GlassScriptPhysician profile
Muhammad S Ghani
NPI 1427055045
$9,109.92
in general payments reported to CMS, 2019-2025
49 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $17.24 · 2021: $96.47 · 2022: $709 · 2023: $1,558 · 2024: $3,403 · 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,616 · Education: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,615.55 |
| Education | $417.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,978.05 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $920.50 | 2022-2025 | |
| Gilead Sciences, INC. | $475.04 | 2021-2025 | Trodelvy |
| Sobi, INC | $473.22 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $442.31 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $437.19 | 2019-2025 | Polivy, Phesgo, Perjeta |
| Tempus Ai, INC | $411.80 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $389.36 | 2019-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $362.34 | 2022-2025 | |
| Celgene Corporation | $288.59 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Karyopharm Therapeutics INC. | $257.72 | 2023-2025 | Xpovio |
| Exelixis INC. | $255.57 | 2021-2025 | Cabometyx |
| Astellas Pharma US INC | $225.15 | 2023-2025 | Xospata, Xtandi, Vyloy |
| Janssen Biotech, INC. | $169.65 | 2023-2025 | Imbruvica, Darzalex, Tecvayli |
| Amgen INC. | $167.75 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $153.77 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $151.06 | 2020-2025 | Eliquis, Opdivo, Opdualag |
| Emd Serono, INC. | $150.82 | 2023-2025 | Bavencio |
| Eisai INC. | $145.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $128.80 | 2022-2025 | Ojjaara |
| Abbvie INC. | $122.91 | 2022-2025 | |
| Genzyme Corporation | $118.65 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $101.47 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $61.61 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $54.64 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $53.98 | 2024 | Krazati |
| Incyte Corporation | $48.99 | 2022-2023 | Monjuvi |
| Genmab U.S., INC. | $48.33 | 2025 | Tivdak, Epkinly |
| Springworks Therapeutics, INC. | $43.66 | 2024 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $42.74 | 2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $34.29 | 2024 | |
| Stemline Therapeutics INC. | $32.88 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $29.87 | 2023 | Rezlidhia, Tavalisse |
| Accord Healthcare, INC. | $29.22 | 2024 | |
| Alexion Pharmaceuticals, INC. | $28.63 | 2024 | Ultomiris |
| Array Biopharma INC | $27.20 | 2025 | Braftovi, Mektovi, Lorbrena |
| Legend Biotech USA INC. | $24.44 | 2025 | Carvykti |
| Taiho Oncology, INC. | $21.67 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.32 | 2025 | |
| Coherus Oncology, INC. | $20.63 | 2024 | |
| Seagen INC. | $20.45 | 2022 | |
| Sirtex Medical INC | $20.17 | 2023 | Sir-Spheres Microspheres |
| Sumitomo Pharma America, INC. | $19.22 | 2024 | Orgovyx |
| Puma Biotechnology, INC. | $18.65 | 2023 | Nerlynx |
| Paratek Pharmaceuticals, INC. | $18.57 | 2024 | Nuzyra |
| Ipsen Biopharmaceuticals, INC | $17.92 | 2025 | Onivyde |
| Lilly USA, LLC | $15.51 | 2024 | Jaypirca, Verzenio |
| Tactile Systems Technology INC | $14.91 | 2022 | |
| Foundation Medicine, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.